Track III: Research
Pharmacogenomics for the Practicing Neuropsychiatric Pharmacist

Log in for full access to this session if you are registered.

Session Summary

Genetic factors can result in variance in drug metabolism enzyme function, which is one major mechanism impacting interindividual variability in therapeutic response and side effects to neuropsychiatric medications. This presentation will discuss the promises of pharmacogenetics in psychiatry with the presentation consisting of three components: 1) Results from a pilot study investigating genetic variants in the drug metabolizing enzymes CYP2D6 and CYP2C19 following antidepressants and antipsychotic treatment, 2) Report on the Pharmacogenetics Research Clinic at our CAMH hospital. Patients with a diagnosis of schizophrenia and mood disorders are being enrolled prospectively and genotyped for CYP2D6 and CYP2C19. 3) Major findings in antipsychotic-induced weight gain (AIWG). Unfortunately, AIWG has become a common side-effect with newer antipsychotics and significantly increases morbidity in patients with schizophrenia.

This presentation will highlight our research in this area. Briefly, 1) Our case-reports suggest a potential clinical benefit of CYP genotyping for specific patients, however further validation of CYP2D6 and CYP2C19 testing in prospective, randomized trials is warranted. 2) Our findings suggest that CYP2D6 and CYP2C19 genotyping provides useful information that help physicians to improve pharmacotherapy for individual patients. 3) Our results tentatively suggest novel associations between functionally relevant gene variants in patients treated with antipsychotic medication for schizophrenia.

In this session, implications for treatment in clinical practice will be discussed as well as potential opportunities in drug discovery and drug development, arising from findings in pharmacogenomic studies.

Faculty Information

Daniel Mueller, MD, PhD

View biographical information and disclosures

Learning Objectives

  1. Illustrate the implications of gene variation.
  2. Summarize the current use of pharmacogenomic testing in clinical practice.
  3. Discuss clinical examples of the benefits of the tests.
  4. Explain how to assess “clinical utility” when practicing individualized medicine.

Continuing Education Credit

Activity Date: 05/01/2012
ACPE Contact Hours: 1.0
ACPE Number: 0284-9999-12-019-L04-P (Knowledge)
ACCME: 1 AMA PRA Category 1 Credit(s)™
Nursing Credit Reminder: Note that ACPE and ACCME credit is accepted for certification renewal.

Course Requirements

This session is presented live at the 2012 CPNP Annual Meeting. A PDF file of the slides is provided online. Access to the online PDF content is available to participants indefinitely although ACPE credit is available only through the Annual Meeting. To obtain continuing education credit, attendees of this session must confirm their attendance by completing a session evaluation within two weeks after the session. ACPE transcripts can be retrieved by participants online at cpnp.org and the credit will be automatically submitted to your account at CPE Monitor shortly after the evaluation is completed. CME statements will be issued by the end of June 2012 by the University of Arizona.

Login or register to help identify topics from this page.